Market Summary | Major Indices | Market Movers | Market Sectors | Mutual Funds | A-Z Stock Listings
ETF Screener | World Markets | Currencies | CEO Wealthmeter | Oil / Energy | Metals
Treasury Rates | Calculators | My Watchlist | My Portfolio
         Symbol Lookup
ONCOTHYREON Add to My Watchlist (NSDQ: ONTY) 
Detailed Quote
News
Chart
SEC Filings
Profile
Historical
Options
     Oncothyreon 4.73 -0.07 (-1.54%) 192,075
2601 4th Avenue
Suite 500
Seattle, WA 98121 US
(206) 801-2100
(780) 463-0871 fax
www.oncothyreon.com
CEO Dr. Robert L. Kirkman, M.D.
Auditor Deloitte & Touche LLP
Exchange Traded NQ
ISIN Number US6823241087
CIK Number 1412067
NAICS Code 325414
Business Summary
A clinical-stage biopharmaceutical company, which is focused on the development of therapeutic products for the treatment of cancer.
Number of Employees 18
Share Fundamentals
Market Cap 121.28M
Shares Outstanding 25.66M
Float 23.98M
Short Interest 2.19M
Financial Strength
Revenue (TTM) $36,063,000
Earnings (TTM) $5,975,000
Quick Ratio 14.8:1
Current Ratio 14.9:1
Total Debt/Equity 0.01:1
Profitability
Gross Margin 62.1%
EBITDA Margin 32.8%
Profit Margin 16.6%
Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Market News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs